A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study

M. van Agthoven; C.M. Segeren; I. Buijt; C.A. Uyl-de Groot; B. van der Holt; H.M. Lokhorst; P. Sonneveld

A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study

Translated title of the contribution: A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study

M. van Agthoven, C.M. Segeren, I. Buijt, C.A. Uyl-de Groot, B. van der Holt, H.M. Lokhorst, P. Sonneveld

Hematology/Van Creveldclinic

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study
Original language	Undefined/Unknown
Pages (from-to)	1159-1169
Number of pages	11
Journal	European Journal of Cancer
Volume	40
Publication status	Published - 2004

Cite this

van Agthoven, M., Segeren, C. M., Buijt, I., Uyl-de Groot, C. A., van der Holt, B., Lokhorst, H. M., & Sonneveld, P. (2004). A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study. European Journal of Cancer, 40, 1159-1169.

van Agthoven, M. ; Segeren, C.M. ; Buijt, I. et al. / A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study. In: European Journal of Cancer. 2004 ; Vol. 40. pp. 1159-1169.

@article{39fd2699998847bc9d9366ab23773fe1,

title = "A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study",

author = "{van Agthoven}, M. and C.M. Segeren and I. Buijt and {Uyl-de Groot}, C.A. and {van der Holt}, B. and H.M. Lokhorst and P. Sonneveld",

year = "2004",

language = "Undefined/Unknown",

volume = "40",

pages = "1159--1169",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

van Agthoven, M, Segeren, CM, Buijt, I, Uyl-de Groot, CA, van der Holt, B, Lokhorst, HM & Sonneveld, P 2004, 'A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study', European Journal of Cancer, vol. 40, pp. 1159-1169.

A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study. / van Agthoven, M.; Segeren, C.M.; Buijt, I. et al.
In: European Journal of Cancer, Vol. 40, 2004, p. 1159-1169.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study

AU - van Agthoven, M.

AU - Segeren, C.M.

AU - Buijt, I.

AU - Uyl-de Groot, C.A.

AU - van der Holt, B.

AU - Lokhorst, H.M.

AU - Sonneveld, P.

PY - 2004

Y1 - 2004

M3 - Article

SN - 0959-8049

VL - 40

SP - 1159

EP - 1169

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

van Agthoven M, Segeren CM, Buijt I, Uyl-de Groot CA, van der Holt B, Lokhorst HM et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell resuve in newly diagnosed patients with stage I/II multiple myeloma: a prospective randomised phase III study. European Journal of Cancer. 2004;40:1159-1169.